ГИПЕРКАЛЬЦИЕМИЯ В ПРАКТИКЕ ИНТЕРНИСТА
Аннотация
Актуальность изучения гиперкальциемии обусловлена тем, что ее распространенность среди населения в разных популяциях варьирует от 0,17 до 3,9 случаев на 100 человек. Чаще всего гиперкальциемия носит бессимптомный характер, но при этом процесс кальцификации стенок сосудов и внутренних органов, а также резорбция костной ткани приводят к развитию артериальной гипертензии, атеросклероза, остеопороза, увеличивающих риск развития неблагоприятного прогноза, особенно в группе пожилых пациентов. Учитывая, что гиперкальциемия считается достаточно опасным состоянием для жизни человека, врачам разного профиля необходимо уметь своевременно провести диагностику этого состояния с целью назначения адекватного лечения основного заболевания и избежать клинических проявлений как хронической, так и острой гиперкальциемии.
Литература
Demidova TYu, Lobanova KG, Korotkova TN. Hypercalcemia syndrome: differential diagnostic search and treatment tactics. FOCUS. Endocrinology. 2023;4(1):66-77. https://doi.org/10.15829/2713-0177-2023-6. https://www.elibrary.ru/ovsnaj. (Russian).
Papizh SV. Hypercalcemia in children. Nephrology. 2020;24(2):42-51. https://doi.org/10.36485/1561-6274-2020-24-2-42-51. https://www.elibrary.ru/xcetqr. (Russian).
Tinawi M. Disorders of Calcium Metabolism: Hypocalcemia and Hypercalcemia. Cureus. 2021;13(1):e12420. https://doi.org/10.7759/cureus.12420.
Mokrysheva NG, Eremkina AK, Kovaleva EV, Krupinova JA, Vikulova OK. Modern problems of hyper- and hypoparathyroidism. Terapevticheskii Arkhiv. 2021;93(10):1149-1154. https://doi.org/10.26442/00403660.2021.10.201109. https://www.elibrary.ru/zgicrx. (Russian).
Voronkova IA, Eremkina AK, Krupinova YuA, Gurevich LE, Mokrysheva NG. Neuroendocrine markers in parathyroid tumors. Archive of Pathology. 2020;82(6):70-78. https://doi.org/10.17116/patol20208206170. https://www.elibrary.ru/lfqrhb. (Russian).
Mokrysheva NG, Krupinova JA, Voronkova IA. Parathyroid glands: the normal development, anatomy and histological structure. Endocrine Surgery. 2018;12(4):178-187. https://doi.org/10.14341/serg10039. https://www.elibrary.ru/mkrwxf. (Russian).
Mokrysheva NG, Krupinova JA. The history of the discovery of parathyroid glands, and their role in the body. Annals of the Russian Academy of medical sciences. 2019;74(1):35-43. https://doi.org/10.15690/vramn1072. https://www.elibrary.ru/vycopl. (Russian).
Vetchinnikova ON. Hyperparathyroidism and chronic kidney disease. Part 1. Features of pathogenesis, clinical manifestations, diagnostic strategy. Nephrology and dialysis. 2023;25(1):36-56. https://doi.org/10.28996/2618-9801-2023-1-36-56. https://www.elibrary.ru/gxdqqm. (Russian).
Salukhov VV, Kovalevskaya EA, Kurbanova V.V. Osteal and extraosteal effects of vitamin D and its opportunities of medication correction of its deficiency. Medical Council. 2018;(4):90-99. https://doi.org/10.21518/2079-701X-2018-4-90-99. https://www.elibrary.ru/ytzgzd. (Russian).
Bersenev GA, Ilyicheva EA, Bulgatov DA. Disputable Issues of Etiology and Pathogenesis of Tertiary Hyperparathyroidism. Acta Biomedica Scientifica. 2019;4(5):104-115. https://doi.org/10.29413/ABS.2019-4.5.17. https://www.elibrary.ru/ljiwud. (Russian).
Sviridonova MA. Syndrome of hypocalсiuric hypercalcemia. Is it rare? Two clinical cases in an outpatient clinic. Problems of Endocrinology. 2022;68(5):24-31. https://doi.org/10.14341/probl13125. https://www.elibrary.ru/welfyv. (Russian).
Tonon CR, Silva TAAL, Pereira FWL, Queiroz DAR, Junior ELF, Martins D, Azevedo PS, Okoshi MP, Zornoff LAM, de Paiva SAR, Minicucci MF, Polegato BF. A review of current clinical concepts in the pathophysiology, etiology, diagnosis, and management of hypercalcemia. Med Sci Monit. 2022;28:e935821. https://doi.org/10.12659/MSM.935821.
Srinivasan A, Wong FK, Karponis D. Calcitonin: a useful old friend. J Musculoskelet Neuronal Interact. 2020;20(4):600-609.
Mokrysheva NG, Eremkina AK, Mirnaya SS, Krupinova JA, Voronkova IA, Kim IV, Beltsevich DG, Kuznetzov NS, Pigarova EA, Rozhinskaya LYa, Degtyarev MV, Egshatyan LV, Rumiantsev PA, Andreeva EN, Аntsiferov MB, Markina NV, Kryukova IV, Karonova TL, Lukyanov SV, Sleptcov IV, Chagai NB, Melnichenko GA, Dedov II. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. https://doi.org/10.14341/probl12801. https://www.elibrary.ru/gkeejb. (Russian).
Shepelkevich AP, Brutskaya-Stempkovskaya EV, Kostin GM, Losik MV, Chertko EN. Results of a continuous study of hypercalcemia in the adult population of Minsk: clinical outcomes. Laboratory diagnostics. Eastern Europe. 2018;7(3):321-332. edn: YLVNAT. (Russian).
Velichko AV, Veyalkin IV, Rozhko AV, Yarets YuI. The prevalence of hypercalcemia in adult population of the Gomel region. Health and Ecology Issues. 2019;(2):89-94. edn: MOZAZF. (Russian).
Sulaiman S, Mukherjee S, Sharma S, Pal R, Bhadada SK. Prevalence and etiological profile of hypercalcemia in hospitalized adult patients and association with mortality. Indian J Endocrinol Metab. 2022;26(5):453-458. https://doi.org/10.4103/ijem.ijem_223_21.
Majety P, Groysman A, Erlikh N, Chen ZZ, Westcott GP. Predictors of mortality in hypercalcemia of advanced chronic liver disease. Endocr pract. 2022;28(10):1062-1068. https://doi.org/10.1016/j.eprac.2022.07.008.
Motlaghzadeh Y, Bilezikian JP, Sellmeyer DE. Rare causes of hypercalcemia: 2021 update. J Clin Endocrinol Metab. 2021;106(11):3113-3128. https://doi.org/10.1210/clinem/dgab504.
Meehan AD, Udumyan R, Kardell M, Landén M, Järhult J, Wallin G. Lithium-associated hypercalcemia: pathophysiology, prevalence, management. World J Surg. 2018;42(2):415-424. https://doi.org/10.1007/s00268-017-4328-5.
Lee JY, Shoback DM. Familial hypocalciuric hypercalcemia and related disorders. Best Pract Res Clin Endocrinol Metab. 2018;32(5):609-619. https://doi.org/10.1016/j.beem.2018.05.004.
Palumbo VD, Damiano G, Messina M, Fazzotta S, Monte GLo, Monte ILo. Tertiary hyperparathyroidism: a review. Clin Ter. 2021;172(3):241-246. https://doi.org/10.7417/CT.2021.2322.
Chandran M, Wong J. Secondary and tertiary hyperparathyroidism in chronic kidney disease: an endocrine and renal perspective. Indian J Endocrinol Metab. 2019;23(4):391-399. https://doi.org/10.4103/ijem.IJEM_292_19.
Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018;68(5):377-386. https://doi.org/10.3322/caac.21489.
O’Callaghan S, Yau H. Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift. Endocr Connect. 2021;10(1):R13-R24. https://doi.org/10.1530/EC-20-0487.
Caillet P, Goyer-Joos A, Viprey M, Schott AM. Increase of vitamin D assays prescriptions and associated factors: a population-based cohort study. Sci Rep. 2017;7(1):10361. https://doi.org/10.1038/s41598-017-10263-8.
Galior K, Grebe S, Singh R. Development of vitamin D toxicity from overcorrection of vitamin D deficiency: a review of case reports. Nutrients. 2018;10(8):953. https://doi.org/10.3390/nu10080953.
Dorflinger C, Fuller M. Lithium-induced hypercalcemia with normal parathyroid hormone: A case report. Ment Health Clin. 2019;9(5):318. https://doi.org/10.9740/mhc.2019.09.318.
Ministry of Health of the Republic of Belarus. Ob utverzhdenii klinicheskih protokolov. Postanovlenie № 85 (June 21, 2021). [Internet]. Available from: https://pravo.by/document/?guid=12551&p0=W22238190p&p1=1&p5=0. (Russian).
Miyaoka D, Imanishi Y, Kato E, Toi N, Nagata Y, Kurajoh M, Yamada S, Inaba M, Emoto M. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine. 2020;69(3):642-649. https://doi.org/10.1007/s12020-020-02401-6.
Hanna RM, Hasnain H, Sangalang MD, Han J, Arasu A, Arman F, Barsoum M, Poa H, Rastogi A, Harari A. Three patients with lithium-associated hyperparathyroidism: literature review regarding medical and surgical management. Case Rep Nephrol Dial. 2019;9(2):108-118. https://doi.org/10.1159/000502399.
Rehan MA, Rashid A, Krell K, Gabutti C, Singh R. Calcium alkali thiazide syndrome: what we need to know. Cureus. 2020;12(10):e10856. https://doi.org/10.7759/cureus.10856.
Gorvin CM, Hannan FM, Cranston T, Valta H, Makitie O, Schalin‐Jantti C, Thakker RV. Cinacalcet rectifies hypercalcemia in a patient with familial hypocalciuric hypercalcemia type 2 (FHH2) caused by a germline loss-of-function Gα11 mutation. J Bone Miner Res. 2018;33(1):32-41. https://doi.org/10.1002/jbmr.3241.
Dulfer RR, Franssen GJH, Hesselink DA, Hoorn EJ, van Eijck CHJ, van Ginhoven TM. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg. 2017;104(7):804-813. https://doi.org/10.1002/bjs.10554.
Fuleihan GEH, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Poznak CV, Wu JY, Drake MT. Treatment of hypercalcemia of malignancy in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(3):507-528. https://doi.org/10.1210/clinem/dgac621.
